HansGarrincha schreef op 15 november 2018 09:24:
Grazie mille Avanti2!
Raymond James 14 november 2018
Initiating at Strong Buy ($157 Price Target): Filgotinib Emerging as Bestin-Class Recommendation: We initiate coverage of Galapagos (GLPG) with a Strong Buy rating and a $157 12-month price target. Galapagos is a clinical stage biopharma company with a lead drug, filgotinib, which could be approved as a disease modifying drug for multiple auto-immune disorders, beginning with an U.S. FDA approval for the treatment of rheumatoid arthritis during 2020. Our investment thesis is based upon three key points, 1) filgotinib has demonstrated a clear path to approval across multiple indications, supporting our forecast for ~$2.9B in global drug sales during 2023E, 2) clinical data for filgotinib has steadily built evidence that it could be a best-in-class JAK inhibitor, and 3) the Galapagos pipeline of wholly owned therapeutic candidates is expected to rapidly expand over the next several years.